CLINICAL LAB EXPO HALL
Visit AACC 2022 DISRUPTIVE TECHNOLOGY AWARD SEMIFINALIST Biological Dynamics at the Clinical Lab Expo Hall to learn more about our unique technology for early cancer detection. The 2022 AACC Annual Scientific Meeting & Clinical Lab Expo showcases the latest science and technology shaping the future of laboratory medicine. The annual event features vital research and important changes in the field, with more than 250 educational opportunities in the form of lectures, plenary, scientific, and roundtable sessions. SEE DETAILS >>

From Plenaries featuring world-renowned scientists to cutting-edge Scientific Sessions and intimate Roundtables geared for lively discussion on hot topics, the 2022 AACC Annual Scientific Meeting & Clinical Lab Expo offers something for everyone in laboratory medicine.

AACC’s scientific program is designed to provide you with the knowledge you need to advance professionally, the skills to improve your practice, and opportunities to collaborate and learn from experts. Discover the meeting’s more than 250 educational opportunities in a variety of formats spanning the breadth of laboratory medicine. Use the Online Session Search to view the full conference program and find sessions by topic, speaker, or other features.

LIQUID BIOPSY SHOWCASE
PRESENTATION: Thursday, June 30, 2022
2:45 PM PT/5:45 PM ET
SESSION: Liquid Biopsy Showcase

JP Hinestrosa, Ph.D., Sr. Director, Research, Biological Dynamics will discuss the company’s disruptive technology designed to advance early cancer detection by leveraging its proprietary Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.

PRESENTATION ABSTRACT
Exosome Classifier For Early-Stage Cancer Detection
Biological Dynamics is advancing early cancer detection by leveraging its Verita™ platform to capture and analyze exosomes from early-stage (I/II) cancer patient samples. Analysis of exosomal biomarkers enables highly sensitive and specific cancer detection, potentially allowing earlier cancer intervention.

The Liquid Biopsy Showcase features selected liquid biopsy companies that are advancing the development of tests for oncology, immunotherapy, and other areas, based on detection and identification of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), circulating RNA, circulating microRNAs, or extracellular vesicle (exosomes).

PMWC, the “Precision Medicine World Conference” is the largest annual conference dedicated to precision medicine. PMWC’s mission is to bring together recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration in an effort to accelerate the development and spread of precision medicine.

Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology in clinical implementation (e.g., cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors

POSTER PRESENTATION: Friday, May 27, 2022
3:15 PM – 4:15 PM CET
SESSION ROOM: Forum 5 & 6
TITLE: PF01 – Technologies and methods: EV separation from blood

David Searson, Senior Process Engineer, Biological Dynamics to present the company’s latest data for early cancer detection.

PRESENTATION ABSTRACT:
Electrokinetic Isolation of Extracellular Vesicles from Pancreatic, Ovarian and Bladder Cancers Enables Early Detection
Extracellular vesicles (EVs) carry cancer biomarkers and are central to emerging liquid biopsy technologies; however, current EV isolation methods balance purity against efficiency. We investigated an alternating current electrokinetic (ACE) method to isolate EVs directly from plasma. We compared the ACE method against differential ultracentrifugation (DU) to study yield, purity and utility. EVs isolated by ACE were then used for detection of early-stage pancreatic, ovarian, and bladder cancers.

The annual ISEV meeting offers an unparalleled opportunity to learn from, teach, and network with, leading and emerging experts in EV research. The scope and quality of the scientific exchange makes ISEV2022 the world’s largest and the premier meeting in EV research. This event features the best in vesicle science, covering all aspects of fundamental, translational, and clinical research, disseminating cutting-edge developments in EV research. ISEV2022 brings together scientists from academic, clinics, and industry, who have a common goal of understanding EVs and applying this knowledge for societal and economic benefit.

PRESENTATION: Monday, May 16, 2022
7:00 AM. – 9:00 AM CST
PODIUM PD53-07, Room 255/Abstract ID: 22-7466
TITLE: Bladder Cancer – Basic Research & Pathophysiology III

Jean M. Lewis, Ph.D., Associate Director, Research, Biological Dynamics to present the company’s latest bladder cancer data.

PRESENTATION ABSTRACT
Detection of Early-stage Bladder Cancer Using Plasma Extracellular Vesicle Protein Biomarkers
There is a need for earlier bladder cancer screening to reduce lifetime costs and improve patient outcomes. Urinary protein biomarkers have shown some promise, but reported sensitivities appear compromised by low and/or variable biomarker concentrations. In this study, we investigated the potential of using extracellular vesicles (EV) circulating in the blood to detect stage I and II bladder cancer. Using an alternating current electrokinetic (ACE) platform to purify EVs from plasma, we show how a multi-marker EV protein-based methodology can be used to discriminate bladder cancer cases from controls in stage I and II cases.

AUA continues to be a leader in developing innovative, evidence-based quality education for urologists and urologic health care professionals worldwide. Through the Annual Meeting—and other year-round educational offerings—the AUA sets the highest standards for urologic education.

The Annual Meeting, in its 117th year, is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines, and the latest advances in urologic medicine. Attendees repeatedly report that the knowledge they take from the meeting positively impacts their practices.

LIVE PRESENTATION
Sunday, April 10, 2022, 4:20 – 4:35 PM (ET)
SESSION CATEGORY: New Targets and Strategies for Prevention and Risk Reduction
SESSION TITLE: 727 – Detection of early-stage lung cancer using a liquid biopsy test based on extracellular vesicle proteins
PRESENTER: Juan P. Hinestrosa, PhD

VIRTUAL POSTER PRESENTATIONS:
Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Preclinical Prevention, Early Detection, and Interception
SESSION TITLE: 5960 – Blood-based extracellular vesicle biomarker test for detection of early-stage pancreatic cancer
PRESENTER: Juan P. Hinestrosa, PhD

Friday, April 8, 2022, 12:00 PM – 1:00 PM (ET)
SESSION CATEGORY: Chemistry
SESSION TITLE: Proteomics and Mass Spectrometry
PERMANENT ABSTRACT NUMBER: 5082 – Proteomic analysis of extracellular vesicles from oncology donor samples purified using an alternating current electrokinetic microelectrode chip
PRESENTER: Jean M. Lewis, PhD

NOTE: Virtual posters are available online only and will not be presented live. Attendees can send questions to the presenter through the e-poster site or through the Networking feature of the virtual meeting platform. E-posters will be released at 12:00 PM CT on Friday, April 8, and will be available to registered attendees through Wednesday, July 13, 2022.

EVENT: Monday, April 4, 8:00 AM – Tuesday, April 5, 2022, 3:30 PM (ET)

PRESENTATION: Tuesday, April 5, 2022, 9:55 A.M. (ET)

Fireside Chat with Biological Dynamics
Dr. Paul Billings will discuss the interplay between therapeutic and diagnostic development; how molecular diagnostics impact therapeutic development; and using diagnostics to support revisiting data, global development, and global regulatory strategy.

Session Title: What Therapeutic Developers Should Look for in a Diagnostic Partner

CONFERENCE: Tuesday, March 22, 2022, 8:00 AM – Wednesday, March 23, 5:00 PM

OPENING KEYNOTE PANEL: Tuesday, March 22, 2022
9:00 – 9:45 AM
Interpreting the Current Reimbursement Climate for Diagnostic Testing Products

Dr. Paul Billings, Biological Dynamics, to participate in an interactive panel to discuss:
• Lessons learned: A look at strategies used throughout the pandemic
• Considerations impacting coverage for COVID products post-EUA
• Decoding reimbursement coverage trends for new technologies
• Assessing the current landscape regarding VALID & VITAL Acts

VIRTUAL EVENT
Participation: Tuesday, March 8, 2022

Biological Dynamics’ Kevin Han to participate in emerging product discussions on Tuesday, March 8, 2022. More than 375 public and private companies across the entire healthcare spectrum attend the invitation-only event.

The conference program includes high-interest panels covering a range of topics: key medical devices; life science and diagnostic tools; health care delivery; and the evolving political and regulatory landscape, all featuring renowned medical, scientific, industry, legal, and political consultants. Cowen analysts will answer investor questions submitted to the panel, and provide data-rich content to drive deeper discussion and insights, such as a comparison of clinical expert and payor views.

EVENT: Tuesday, March 1, 2022, 08:00 Central European Time (CET) – Wednesday, March 2, 2022, 18:00 (CET)

PRESENTATION: Wednesday, March 2
11:00 AM CET/5:00 AM EST

Dr. Jean M. Lewis, Associate Director of Research at Biological Dynamics, Inc., will discuss her team’s work developing exosome-based liquid biopsy assays using the company’s proprietary platform. The presentation, Multi-Cancer Early Detection Based on a Classifier for Extracellular Vesicle Biomarkers, illustrates the potential utility of EV-protein biomarkers in the non-invasive diagnosis of cancer applications. Recently, her research has been directed towards identifying EV biomarkers for early-stage cancer liquid biopsy.

Presentation Abstract
Simultaneous detection of multiple, early-stage cancers was tested using extracellular vesicle (EV) bound protein markers from plasma purified by an alternating current electrokinetic (ACE) microarray. In a case-control study, this method detected 95.7% of pancreatic, 75.0% of ovarian, and 43.8% of bladder cancers at 99.5% specificity, all at stages I and II. The initial results suggest that this liquid biopsy screen may have great promise for early-stage, multi-cancer screening.

Session Title: Technology Developments in the Circulating Biomarkers Space

SelectBio Circulating Biomarkers Europe brings together academics and industry participants from around the world focused on research, biomarker analyses and therapeutics development leveraging the cargo from Exosomes and Extracellular Vesicles (EVs). An important component of this conference is to focus upon the development of Liquid Biopsies using circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and other biomarkers found in biofluids.

Additionally, the conference focuses on the Therapeutic and Drug Delivery Opportunities Enabled by Extracellular Vesicles (EVs). In this vein, key opinion leaders in this space will be presenting at this conference.

Presentations, Panel Discussions and Round-Table Workshops from key opinion leaders in the field form the basis of this conference.

Monday, December 13, 2021, 1:00 PM PT/4:00 PM ET – Wednesday, Dec 15, 2021, 5:30 PM PT/8:30 PM, ET

Biological Dynamics presents a poster based on the recent study:
Isolation of extracellular vesicles from ovarian, bladder, and pancreatic cancer patient plasma using novel microelectrode array technology compared to ultracentrifugation